GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinomed Biotech AG (STU:93Z) » Definitions » 3-Year EPS without NRI Growth Rate

Marinomed Biotech AG (STU:93Z) 3-Year EPS without NRI Growth Rate : -3.20% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Marinomed Biotech AG 3-Year EPS without NRI Growth Rate?

Marinomed Biotech AG's EPS without NRI for the three months ended in Mar. 2024 was €-1.40.

During the past 3 years, the average EPS without NRI Growth Rate was -3.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 9 years, the highest 3-Year average EPS without NRI Growth Rate of Marinomed Biotech AG was 20.10% per year. The lowest was -105.80% per year. And the median was -19.50% per year.


Competitive Comparison of Marinomed Biotech AG's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Marinomed Biotech AG's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marinomed Biotech AG's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Marinomed Biotech AG's 3-Year EPS without NRI Growth Rate falls into.



Marinomed Biotech AG 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Marinomed Biotech AG  (STU:93Z) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Marinomed Biotech AG 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Marinomed Biotech AG's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Marinomed Biotech AG Business Description

Industry
Traded in Other Exchanges
Address
Hovengasse 25, Korneuburg, AUT, 2100
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The products marketed by the company are based on its platform Carragelose and Marinosolv. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.

Marinomed Biotech AG Headlines

No Headlines